Short answer
FENNEC PHARMACEUTICALS INC. (FENC) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $20M (up 57.3% year over year) with net income of $5M.
Q3 2026 key financials · XBRL
- Revenue
- $20M
- +57.3% YoY · +9.7% QoQ
- Net income
- $5M
- +828.4% YoY · +135.2% QoQ
- Operating margin
- 23.7%
- EPS (diluted)
- $0.13
- +750.0% YoY · +160.0% QoQ
Source: XBRL data from the FENNEC PHARMACEUTICALS INC. (FENC) Q3 2026 10-Q on SEC EDGAR. USD.
FENNEC PHARMACEUTICALS INC. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $19,608, up $7,146 YoY, including PEDMARK sales $19,425, up 56% from $12,462
- Cost of product sales margin 4% vs 5% YoY, driven by manufacturing and inventory efficiencies
- Best performer: PEDMARK product sales, $19,425, up $6,963 YoY; only commercial product disclosed
- Cash $48,684 vs $36,788 at December 31, 2025; operating cash flow $9,111 vs $(6,511)
- Outlook: Japan registration strategy and partnering discussions ongoing; additional European launches planned in 2026
Risk Factors
- No material changes from 10-K risk factors disclosed this quarter
- Carried-forward business risk: disclosed risks could impair future growth prospects
- Carried-forward financial risk: disclosed risks could adversely affect financial condition
- Carried-forward operating risk: disclosed risks could harm results of operations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other FENNEC PHARMACEUTICALS INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.